Special Investigation (Long-term Investigation) in Patients With Crohn's Disease
Phase of Trial: Phase IV
Latest Information Update: 21 Apr 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Abbott Laboratories; AbbVie
- 12 Apr 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 31 Oct 2018 to 31 Mar 2018.
- 30 Jan 2018 Planned primary completion date changed from 31 Oct 2018 to 31 Mar 2018.